Partnership Brings Elution Method to Markets

Bio-chromatography development and manufacturing company BIA Separations (Ajdovscina, Slovenia) has signed a licensing agreement with the University of Zagreb (Croatia) to commercialise a novel elution method that helps preserve the integrity, infectivity and potency of viruses during immunoaffinity purification. The University will provide access to proprietary technology, which the company BIA Separations will market to biopharma, biotech and life science industries globally. Research teams from both organisations will collaborate to develop follow-on technologies to support the purification of viruses and viral vectors for research and clinical use. 

BIA Separations is focused on the manufacture of gene therapy vectors, vaccines, exosomes, DNA/RNA and any novel complex biopharma product. CEO Ales Strancar, said “In order to achieve fully integrated upstream and downstream processing with robust in-process control we are collaborating with other leaders in the industry to access the latest technologies and products. This agreement with the University of Zagreb is one of a number currently in the pipeline and supports our ultimate goal.”

Professor Miljenko Simpraga, Vice-rector for Innovation, Technology Transfer and Communication at the University of Zagreb added: “The University of Zagreb is pleased to see solutions developed by our researchers contributing to improvements in medical biotechnology, and being brought closer to users through our work with innovation-oriented industry partners such as BIA Separations. As a research university, this is an important achievement which is fully aligned with our aim to create a positive impact on society.”